Hengrui Pharma (600276.SH) announced that the company has received a Filing Communication from the U.S. Food and Drug Administration (FDA), indicating that its resubmitted Biologics License Application (BLA) for camrelizumab injection in combination with apatinib mesylate tablets as a first-line treatment for patients with unresectable or metastatic hepatocellular carcinoma has been accepted for review. According to the Prescription Drug User Fee Act (PDUFA), the FDA has set a target action date of July 23, 2026, for the review of camrelizumab injection.